tbuckley/cabot-search huggingface dataset:
Comparison of the paper‐based and electronic versions of the Dermatology Life Quality Index: evidence of equivalence
Authors: F.M. Ali, N. Johns, A.Y. Finlay, M.S. Salek, V. Piguet
Journal: British Journal of Dermatology (2017)

The use of patient‐reported outcome measures in electronic format has been increasing. However, these formats are usually not validated or compared with the original paper‐based formats, so there is no evidence that they are completed in the same way. To compare the conventional paper version with a web‐based application (iPad®) version of the Dermatology Life Quality Index (DLQI) to assess equivalence of scores. The study employed a randomized crossover design using a within‐subjects comparison of the two formats of the questionnaire. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) guidelines were followed. Participants aged over 18 years with any confirmed skin condition were recruited from a teaching hospital dermatology outpatient clinic. Expected intraclass correlation coefficient (ICC) was 0·9 (α = 0·05). A total of 104 patients were recruited, median age 53·5 years (interquartile range 37·3–67·8; 43% male). The ICC showed high concordance between the total DLQI scores from paper and iPad versions (ICC 0·98; 95% confidence interval 0·97–0·99). Patients took a median of 78 s to complete the electronic version and 73 s for paper (P = 0·008): 76% preferred the electronic version and perceived completion to take a shorter time. There is high concordance and thus equivalence between the iPad and paper versions of the DLQI, with an ICC of 0·98, and a clear patient preference for the iPad version.
Adult Bone Marrow-Derived Cell Fusion with Cardiomyocytes and Purkinje Neurons in Response to Irradiation but Not in Steady State.
Authors: Jens M. Nygren, Simon Stott, Karina Liuba, Martin Breitbach, Willhelm Röll, Bernd Fleischmann, Deniz Kirik, Anders Björklund, Sten Eirik W. Jacobsen
Journal: Blood (2004)
Efficiency of Homing and Engraftment Is Higher in VEGFR-3+CD34+CD38- Cells Than in VEGFR-3-CD34+CD38- Cells in Leukemic Patients
Authors: Heeje Kim, Ji-Yoon Lee, Sohye Park, Jae-Ho Yoon, Woo-Sung Min, Lee Jung-Lim
Journal: Blood (2014)
Highly Accurate Rhesus and Kell Blood Group Phenotyping of Autologous Red Cells after Allogeneic Blood Transfusion Using a Simplified Method of Microhematocrit Centrifugation and Automation with the DiaMed Classic ID-Gel Station and Diaclon ’Rh Subgroups+K’ Gel Cards.
Authors: Philip T. Murphy, Tom Byrne, Sinead A. Moran
Journal: Blood (2007)
Patient- versus physician-reported outcomes in patients enrolled in a prospective study involving stereotactic body radiation therapy in unresectable or recurrent pancreatic cancer.
Authors: Lauren M. Rosati, Zhi Cheng, Scott P. Robertson, Megan N. Kummerlowe, Amy Hacker-Prietz, Timothy M. Pawlik, Christopher Lee Wolfgang, Dung T Le, Lei Zheng, Dan Laheru, Joseph M. Herman
Journal: Journal of Clinical Oncology (2015)

84 Background: Prospective evaluation of correlations between patient- (PROs) and physician-reported outcomes (PhROs) was conducted among a group of patients receiving stereotactic body radiation therapy (SBRT) for recurrent or locally advanced pancreatic cancer (PCA). Methods: Forty-two patients were treated with 25-33 Gy using SBRT in 5 fractions on a single-institution study. Eight outcomes (performance status, fatigue, pain, anorexia, nausea, vomiting, constipation, and diarrhea) were consistently evaluated by patients and providers prior to SBRT and 4-6 weeks post-SBRT. Patient-reported quality of life (QOL) metrics were assessed using the EORTC QLQ-C30 and QLQ-PAN26, while physician-reported toxicities were graded using the NCI CTCAE v4.0.A Pearson’s correlation was used to determine the relationship between PROs and PhROs. Results: Of the 42 enrolled patients, 36 had both PROs and PhROs collected before (median, 2.9 weeks) SBRT. Physician-reported pain, nausea, constipation, and diarrhea did not show a correlation with patient-reported overall health or QOL. Physician-reported fatigue showed a correlation with patient-reported pain (r &gt; 0.5, p &lt; 0.001) and QOL (r &gt; -0.5, p &lt; 0.001) but not fatigue (r &lt; 0.3, p &gt; 0.05). Nausea and constipation were the only PROs that did not correlate with their respective PhROs (nausea, r &lt; 0.3, p &gt; 0.05; constipation, r &lt; 0.5, p = 0.07) or any of the other 7 PhROs. Only 24 had both PROs and PhROs collected 4-6 weeks after (median, 5.1 weeks) SBRT. Vomiting, constipation, and diarrhea were PhROs that demonstrated no correlation with patient-reported overall health or QOL. Physician-reported vomiting did not correlate with patient-reported vomiting (r &lt; 0.3, p &gt; 0.05) or any of the 7 other PROs. The correlation between patient- and physician-reported pain increased from pre- (r &gt; 0.3, p = 0.03) to post- (r &gt; 0.7, p &lt; 0.0001) SBRT. Conclusions: Discrepancies among PROs and PhROs appear to exist in pancreatic-specific outcomes of interest such as constipation and diarrhea. Future health care teams may find it helpful to consider PROs to better manage symptoms and deliver more personalized care. Clinical trial information: NCT01781728.
Bezlotoxumab for Prevention of Recurrent<i>Clostridium difficile</i>Infection
Authors: Mark H Wilcox, Dale N Gerding, Ian R Poxton, Ciaran Kelly, Richard Nathan, Thomas Birch, Oliver A Cornely, Galia Rahav, Emilio Bouza, Christine Lee, Grant Jenkin, Werner Jensen, You-Sun Kim, Junichi Yoshida, Lori Gabryelski, Alison Pedley, Karen Eves, Robert Tipping, Dalya Guris, Nicholas Kartsonis, Mary-Beth Dorr
Journal: New England Journal of Medicine (2017)

Clostridium difficile is the most common cause of infectious diarrhea in hospitalized patients. Recurrences are common after antibiotic therapy. Actoxumab and bezlotoxumab are human monoclonal antibodies against C. difficile toxins A and B, respectively.We conducted two double-blind, randomized, placebo-controlled, phase 3 trials, MODIFY I and MODIFY II, involving 2655 adults receiving oral standard-of-care antibiotics for primary or recurrent C. difficile infection. Participants received an infusion of bezlotoxumab (10 mg per kilogram of body weight), actoxumab plus bezlotoxumab (10 mg per kilogram each), or placebo; actoxumab alone (10 mg per kilogram) was given in MODIFY I but discontinued after a planned interim analysis. The primary end point was recurrent infection (new episode after initial clinical cure) within 12 weeks after infusion in the modified intention-to-treat population.In both trials, the rate of recurrent C. difficile infection was significantly lower with bezlotoxumab alone than with placebo (MODIFY I: 17% [67 of 386] vs. 28% [109 of 395]; adjusted difference, -10.1 percentage points; 95% confidence interval [CI], -15.9 to -4.3; P<0.001; MODIFY II: 16% [62 of 395] vs. 26% [97 of 378]; adjusted difference, -9.9 percentage points; 95% CI, -15.5 to -4.3; P<0.001) and was significantly lower with actoxumab plus bezlotoxumab than with placebo (MODIFY I: 16% [61 of 383] vs. 28% [109 of 395]; adjusted difference, -11.6 percentage points; 95% CI, -17.4 to -5.9; P<0.001; MODIFY II: 15% [58 of 390] vs. 26% [97 of 378]; adjusted difference, -10.7 percentage points; 95% CI, -16.4 to -5.1; P<0.001). In prespecified subgroup analyses (combined data set), rates of recurrent infection were lower in both groups that received bezlotoxumab than in the placebo group in subpopulations at high risk for recurrent infection or for an adverse outcome. The rates of initial clinical cure were 80% with bezlotoxumab alone, 73% with actoxumab plus bezlotoxumab, and 80% with placebo; the rates of sustained cure (initial clinical cure without recurrent infection in 12 weeks) were 64%, 58%, and 54%, respectively. The rates of adverse events were similar among these groups; the most common events were diarrhea and nausea.Among participants receiving antibiotic treatment for primary or recurrent C. difficile infection, bezlotoxumab was associated with a substantially lower rate of recurrent infection than placebo and had a safety profile similar to that of placebo. The addition of actoxumab did not improve efficacy. (Funded by Merck; MODIFY I and MODIFY II ClinicalTrials.gov numbers, NCT01241552 and NCT01513239 .).
Second Neoplasms After Treatment of Childhood Acute Lymphoblastic Leukemia
Authors: Kjeld Schmiegelow, Mette Levinsen, Andishe Attarbashi, Andre Baruchel, Meenakshi Devidas, Gabriele Escherich, Brenda Gibson, Christiane Heydrich, Keizo Horibe, Yasushi Ishida, Der-Cherng Liang, Franco Locatelli, Gerard Michel, Rob Pieters, Caroline Piette, Ching-Hon Pui, Susana C. Raimondi, Lewis B. Silverman, Martin Stanulla, Batia Stark, Naomi Winick, Maria Grazia Valsecchi
Journal: Blood (2012)
Single Cell Network Profiling as a Tool to Identify AML Chemotherapy Resistant Cell Phenotypes Under In Vivo Therapeutic Pressure.
Authors: Alessandra Cesano, John Woronicz, Aileen Cleary Cohen, Todd Covey, Santosh Putta, Urte Gayko, Wendy J. Fantl, S.M. Kornblau
Journal: Blood (2009)
Therapy Personalization Using Predictive Simulation Approach with Ex-Vivo Clinical Validations
Authors: Nicole A Doudican, Ravi Vij, Mark A Fiala, Justin King, Shireen Vali, Kabya Basu, Ansu Kumar, Neeraj Kumar Singh, Zeba Sultana, Taher Abbasi, Amitabha Mazumder
Journal: Blood (2014)
Cytosolic 5′-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis
Authors: J B Lilleker, A Rietveld, S R Pye, K Mariampillai, O Benveniste, M T J Peeters, J A L Miller, M G Hanna, P M Machado, M J Parton, K R Gheorghe, U A Badrising, I E Lundberg, S Sacconi, M K Herbert, N J McHugh, B R F Lecky, C Brierley, D Hilton-Jones, J A Lamb, M E Roberts, R G Cooper, C G J Saris, G J M Pruijn, H Chinoy, B G M van Engelen
Journal: Annals of the Rheumatic Diseases (2017)

Autoantibodies directed against cytosolic 5'-nucleotidase 1A have been identified in many patients with inclusion body myositis. This retrospective study investigated the association between anticytosolic 5'-nucleotidase 1A antibody status and clinical, serological and histopathological features to explore the utility of this antibody to identify inclusion body myositis subgroups and to predict prognosis. Data from various European inclusion body myositis registries were pooled. Anticytosolic 5'-nucleotidase 1A status was determined by an established ELISA technique. Cases were stratified according to antibody status and comparisons made. Survival and mobility aid requirement analyses were performed using Kaplan-Meier curves and Cox proportional hazards regression. Data from 311 patients were available for analysis; 102 (33%) had anticytosolic 5'-nucleotidase 1A antibodies. Antibody-positive patients had a higher adjusted mortality risk (HR 1.89, 95% CI 1.11 to 3.21, p=0.019), lower frequency of proximal upper limb weakness at disease onset (8% vs 23%, adjusted OR 0.29, 95% CI 0.12 to 0.68, p=0.005) and an increased prevalence of excess of cytochrome oxidase deficient fibres on muscle biopsy analysis (87% vs 72%, adjusted OR 2.80, 95% CI 1.17 to 6.66, p=0.020), compared with antibody-negative patients. Differences were observed in clinical and histopathological features between anticytosolic 5'-nucleotidase 1A antibody positive and negative patients with inclusion body myositis, and antibody-positive patients had a higher adjusted mortality risk. Stratification of inclusion body myositis by anticytosolic 5'-nucleotidase 1A antibody status may be useful, potentially highlighting a distinct inclusion body myositis subtype with a more severe phenotype.
Challenges in fecal donor selection and screening for fecal microbiota transplantation: A review
Authors: Michael H. Woodworth, Cynthia Carpentieri, Kaitlin L. Sitchenko, Colleen S. Kraft
Journal: Gut Microbes (2017)

Fecal microbiota transplantation is best understood as an effective and inexpensive therapy for recurrent Clostridium difficile infection but fecal donor selection and screening should be periodically revised. Here, we review current recommendations for selection and screening of fecal donors for fecal microbiota transplantation. We recommend considering diabetes mellitus, prior cardiovascular events, and clinical healthcare exposure as fecal donor exclusion criteria until more is known about the association of these conditions with the human gut microbiome. We review the non-bacterial members of the human gut microbiome, associations of the gut microbiome with colorectal malignancies, the human gut resistome and how these may impact future donor screening recommendations. Collaboration between clinicians, clinical laboratory scientists, industry and regulatory agencies will be critically important for continued improvement in donor selection and screening.
A Retrospective Hospital Based Study of 440 Patients of Aplastic Anemia from India: Epidemiology; Response to Therapy; and Possible Significance of Jaundice during Therapy.
Authors: Rajat Kumar, Dharma R. Choudhary, Manoranjan Mahapatra, Atul Kotwal, Alka Mathur, Krishan Gopal, T. Chatterjee, R. Saxena, V. P. Choudhry
Journal: Blood (2004)
2016 Rio Olympics: an epidemiological study of the men’s and women’s Rugby-7s tournaments
Authors: Colin W Fuller, Aileen Taylor, Martin Raftery
Journal: British Journal of Sports Medicine (2017)

To determine the incidence, severity and nature of injuries sustained during the men's and women's 2014/2015 and 2015/2016 Sevens World Series (SWS) and 2016 Olympic Games Rugby Sevens tournaments.A prospective cohort study.All players from the core teams competing in the men's and women's 2014/2015 and 2015/2016 SWS (men: 15 teams; women: 11 teams) and all players from the men's (12 teams) and women's (12 teams) 2016 Rio Olympics tournaments.The gold, silver and bronze medal-winning women's teams contained bigger players (body mass and stature) than other teams but the men's medal winning teams came from across the size spectrum of men's teams competing at Rio 2016. The incidences of injury in the men's tournaments (2014/2015 SWS: 107.7 injuries/1000 player-match-hours (95% CI 90.9 to 127.4); 2015/2016 SWS: 109.7 (95% CI 93.7 to 128.6); Rio 2016: 124.5 (95% CI 73.7 to 210.2)) were higher but not statistically significant than those in the equivalent women's tournaments (2014/2015 SWS: 88.5 (95% CI 68.4 to 114.5), p=0.250; 2015/2016 SWS: 109.4 (95% CI 84.2 to 142.2), p=0.984; Rio 2016: 71.1 (95% CI 35.6 to 142.2), p=0.208). There were no statistically significant differences between the incidences of injury at the men's and women's 2016 Rio Olympics and the equivalent 2014/2015 (men: p=0.603; women: p=0.562) and 2015/2016 (men: p=0.652; women: p=0.254) SWS.The incidence, severity and nature of the injuries sustained during the men's and women's Rio 2016 Rugby-7s tournaments fell within the normal range of values for international Rugby-7s tournaments.
Outcomes of UCB transplantation are comparable in FLT3+ AML: results of CIBMTR, EUROCORD and EBMT collaborative analysis
Authors: C Ustun, F Giannotti, M-J Zhang, H-L Wang, C Brunstein, M Labopin, V Rocha, M de Lima, F Baron, B M Sandmaier, M Eapen, E Gluckman, A Nagler, D J Weisdorf, A Ruggeri
Journal: Leukemia (2017)
IL-17A-Expressing CD4+ T Cells Must Acquire the Expression of T-Bet and IFN-γto Destroy Tumor Cells In Vivo.
Authors: Pawel Muranski, Sid P Kerkar, Zachary A Borman, Robert Reger, Luis Sanchez-Perez, Christian S Hinrichs, Zhiya Yu, Douglas C Palmer, Luca Gattinoni, Nicholas P. Restifo
Journal: Blood (2009)
Abnormal neurogenesis and cortical growth in congenital heart disease
Authors: Paul D. Morton, Ludmila Korotcova, Bobbi K. Lewis, Shivaprasad Bhuvanendran, Shruti D. Ramachandra, David Zurakowski, Jiangyang Zhang, Susumu Mori, Joseph A. Frank, Richard A. Jonas, Vittorio Gallo, Nobuyuki Ishibashi
Journal: Science Translational Medicine (2017)

Congenital heart disease depletes SVZ neural stem/progenitor cell pools critical for normal cortical growth.
Anti-CD20-interleukin-21 fusokine targets malignant B cells via direct apoptosis and NK-cell–dependent cytotoxicity
Authors: Shruti Bhatt, Salma Parvin, Yu Zhang, Hyun-Mi Cho, Kranthi Kunkalla, Francisco Vega, John M. Timmerman, Seung-Uon Shin, Joseph D. Rosenblatt, Izidore S. Lossos
Journal: Blood (2017)
Antithrombotic and Hemorrhagic Effects of DU-176b, a Novel, Potent and Orally Active Direct Factor Xa Inhibitor: A Wider Safety Margin Compared to Heparins and Warfarin.
Authors: Taketoshi Furugohri, Yuko Honda, Chikako Matsumoto, Koji Isobe, Nobutoshi Sugiyama, Yoshiyuki Morishima, Toshiro Shibano
Journal: Blood (2004)
Long Term Follow up of Hairy Cell Leukemia (HCL) Patients (PTS) Treated with Interferon-Alpha (IFN-α). The Importance of Maintenance.
Authors: Sotirios Sachanas, Maria K. Angelopoulou, Konstantinos Anargyrou, Styliani I. Kokoris, Theodoros P. Vassilakopoulos, Zacharoula I. Galani, Evangelia M. Dimitriadou, Marina P. Siakantaris, Maria N. Dimopoulou, Flora N. Kontopidou, Marie-Christine Kyrtsonis, Eleni Plata, Panayiotis Tsaftaridis, Panayiotis Panayiotidis, Gerassimos A. Pangalis
Journal: Blood (2006)
The Complexity of Interpreting Genomic Data in Patients with Primary and Secondary Acute Myeloid Leukemia (AML)
Authors: Aziz Nazha, Ahmad Zarzour, Tomas Radivoyevitch, Hetty E. Carraway, Jennifer S. Carew, Cassandra M Hirsch, Kassy E Kneen, Bartlomiej Przychodzen, Bhumika J. Patel, Michael Clemente, Srinivasa R. Sanikommu, Matt Kalaycio, Jaroslaw P. Maciejewski, Mikkael A. Sekeres
Journal: Blood (2015)
Targeting the Human Notch 2-BCR Axis: A Driver of B-Cell Hyper-Responsiveness in Active Chronic Graft-Versus Host Disease (cGVHD)
Authors: Jonathan C. Poe, Wei Jia, Zhiguo Li, Frances T. Hakim, Steven Z. Pavletic, Jeremy J. Rose, David A. Rizzieri, Yiping Yang, Benny J. Chen, Michael Green, Sarah Anand, Christian W. Siebel, Ivan Maillard, Nelson J. Chao, Stefanie Sarantopoulos
Journal: Blood (2015)
Tracing the Pre-B to Immature B Cell Transition in Human Leukemia Cells Reveals a Coordinated Sequence of Primary and Secondary IGK Gene Rearrangement, IGK Deletion and IGL Gene Rearrangement.
Authors: Florian Klein, Niklas Feldhahn, Jana L. Mooster, Peter Wernet, Markus Müschen
Journal: Blood (2004)
Alterations in the Immune Cell Composition in Premalignant Breast Tissue that Precede Breast Cancer Development
Authors: Amy C. Degnim, Tanya L. Hoskin, Muhammad Arshad, Marlene H. Frost, Stacey J. Winham, Rushin A. Brahmbhatt, Alvaro Pena, Jodi M. Carter, Melody L. Stallings-Mann, Linda M. Murphy, Erin E. Miller, Lori A. Denison, Celine M. Vachon, Keith L. Knutson, Derek C. Radisky, Daniel W. Visscher
Journal: Clinical Cancer Research (2017)

Purpose: Little is known about the role of the immune system in the earliest stages of breast carcinogenesis. We studied quantitative differences in immune cell types between breast tissues from normal donors and those from women with benign breast disease (BBD).Experimental Design: A breast tissue matched case-control study was created from donors to the Susan G. Komen for the Cure Tissue Bank (KTB) and from women diagnosed with BBD at Mayo Clinic (Rochester, MN) who either subsequently developed cancer (BBD cases) or remained cancer-free (BBD controls). Serial tissue sections underwent immunostaining and digital quantification of cell number per mm2 for CD4+ T cells, CD8+ T cells, CD20+ B cells, and CD68+ macrophages and quantification of positive pixel measure for CD11c (dendritic cells).Results: In 94 age-matched triplets, BBD lobules showed greater densities of CD8+ T cells, CD11c+ dendritic cells, CD20+ B cells, and CD68+ macrophages compared with KTB normals. Relative to BBD controls, BBD cases had lower CD20+ cell density (P = 0.04). Nearly 42% of BBD cases had no CD20+ B cells in evaluated lobules compared with 28% of BBD controls (P = 0.02). The absence of CD20+ cells versus the presence in all lobules showed an adjusted OR of 5.7 (95% confidence interval, 1.4-23.1) for subsequent breast cancer risk.Conclusions: Elevated infiltration of both innate and adaptive immune effectors in BBD tissues suggests an immunogenic microenvironment. The reduced B-cell infiltration in women with later breast cancer suggests a role for B cells in preventing disease progression and as a possible biomarker for breast cancer risk. Clin Cancer Res; 23(14); 3945-52. ©2017 AACR.
Каріометрична характеристика гепатоцитів на різних стадіях фіброзування та портальної гіпертензії у хворих на хронічні дифузні захворювання печінки
Authors: Yu.M. Stepanov, Yu.A. Haidar, V.I. Didenko, H.Yu. Arzhanova
Journal: GASTROENTEROLOGY (2020)

Обстежені 33 хворі, у двох випадках у біопсійному матеріалі були відсутні ознаки фіброзування печінки, 10 з обстежених мали стадію фіброзу F1, 10 — F2, 6 — F3 і 5 — F4 за шкалою METAVIR. Вимірювали площу ядер гепатоцитів, розраховували коефіцієнт ядерно-цитоплазматичного відношення, коефіцієнт еліптичності та фактор деформації ядер гепатоцитів.Кореляційний зв’язок між каріометричними параметрами гепатоцитів відображає субклітинний механізм порушення при хронічних дифузних захворюваннях печінки на різних стадіях прояву портальної гіпертензії та фіброзування печінки. Виявлена кореляційна залежність збільшення діаметра синусоїдів із прогресуванням проявів портальної гіпертензії.
Breast Cancer Screening in Denmark
Authors: Karsten Juhl Jørgensen, Peter C. Gøtzsche, Mette Kalager, Per-Henrik Zahl
Journal: Annals of Internal Medicine (2017)

Background: Effective breast cancer screening should detect early-stage cancer and prevent advanced disease. Objective: To assess the association between screening and the size of detected tumors and to estimate overdiagnosis (detection of tumors that would not become clinically relevant). Design: Cohort study. Setting: Denmark from 1980 to 2010. Participants: Women aged 35 to 84 years. Intervention: Screening programs offering biennial mammography for women aged 50 to 69 years beginning in different regions at different times. Measurements: Trends in the incidence of advanced (>20 mm) and nonadvanced (≤20 mm) breast cancer tumors in screened and nonscreened women were measured. Two approaches were used to estimate the amount of overdiagnosis: comparing the incidence of advanced and nonadvanced tumors among women aged 50 to 84 years in screening and nonscreening areas; and comparing the incidence for nonadvanced tumors among women aged 35 to 49, 50 to 69, and 70 to 84 years in screening and nonscreening areas. Results: Screening was not associated with lower incidence of advanced tumors. The incidence of nonadvanced tumors increased in the screening versus prescreening periods (incidence rate ratio, 1.49 [95% CI, 1.43 to 1.54]). The first estimation approach found that 271 invasive breast cancer tumors and 179 ductal carcinoma in situ (DCIS) lesions were overdiagnosed in 2010 (overdiagnosis rate of 24.4% [including DCIS] and 14.7% [excluding DCIS]). The second approach, which accounted for regional differences in women younger than the screening age, found that 711 invasive tumors and 180 cases of DCIS were overdiagnosed in 2010 (overdiagnosis rate of 48.3% [including DCIS] and 38.6% [excluding DCIS]). Limitation: Regional differences complicate interpretation. Conclusion: Breast cancer screening was not associated with a reduction in the incidence of advanced cancer. It is likely that 1 in every 3 invasive tumors and cases of DCIS diagnosed in women offered screening represent overdiagnosis (incidence increase of 48.3%). Primary Funding Source: None.